Publications — Semenov Lab | Harvard Dermatology AI Research

J Invest Dermatol 2026

Incubating Artificial Intelligence (AI) Initiatives and Careers in Dermatology

Wongvibulsin S, …, Semenov YR et al.

JAMA Dermatology 2026

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma

Said JT, …, Semenov YR et al.

J Am Acad Dermatol 2026

Risk and protective factors for uveal melanoma: A population-level analysis

Lu C, …, Semenov YR et al.

JAMA Dermatology 2026

Identification of Risk Factors for Acral Melanoma in US Veterans

Hwang JC, …, Semenov YR et al.

British Journal of Dermatology 2026

The Impact of Clinicopathologic Features on the Prognosis of Thin Melanomas: A Retrospective Cohort Analysis

Beagles E, Khattab S, …, Semenov YR et al.

JCI Insight 2026

Somatic Mutations Reveal Hyperactive Notch Signaling in Prurigo Nodularis

Rajeh A, …, Semenov YR et al.

JAAD International 2026

Development and Validation of the Oxford Attitudes to Artificial Intelligence in Medicine Scale

Kantor J, …, Semenov YR et al.

J Immunother Cancer 2025

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Khattab S, Wan G, …, Semenov YR et al.

J Am Acad Dermatol 2025

Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors

Azin M, …, Semenov YR et al.

J Am Acad Dermatol 2025

Clinicopathologic Attributes and Downstream Outcomes of Mucosal Melanomas: A Multihospital Cohort Study

Khattab S, …, Semenov YR et al.

Trans Machine Learning Research 2025

Multi-modal foundation models for computational pathology: a survey

Li D, Wan G, …, Semenov YR et al.

Dermatologic Clinics 2025

The Current State and Future Prospects for Artificial Intelligence in Dermatology

Thang CJ, …, Semenov YR et al.

JAAD International 2025

Exposure to intravenous immunoglobulin is associated with increased mortality in patients on immune checkpoint inhibitors: A population-based cohort study

Cheng D, Nguyen NTT, …, Semenov YR et al.

npj Digital Medicine 2025

Academia loses its grip on digital health solutions as innovation in artificial intelligence shifts towards industry

Hijaz B, …, Semenov YR et al.

Lancet Oncology 2024

Multi-organ immune-related adverse events associated with immune checkpoint inhibitor therapy

Wan G, …, Semenov YR et al.

J Immunother Cancer (JITC) 2024

Defining D-irAEs: consensus-based disease definitions for the diagnosis and severity grading of dermatologic immune-related adverse events

Chen ST*, Semenov YR*, Gabel CK, Leventhal JS, … et al. (*co-first)

J Am Acad Dermatol 2024

Development and validation of time-to-event models to predict distant recurrence of localized melanoma

Wan G, …, Semenov YR et al.

Briefings in Bioinformatics 2024

SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data

Wan G, …, Semenov YR et al.

J Am Acad Dermatol 2023

Cutaneous immune-related adverse events are associated with improved survival in patients with melanoma treated with immune checkpoint inhibitors

Wan G, …, Semenov YR et al.

JAMA Dermatology 2022

Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-PD-1 and anti-PD-L1 therapy

Tang T, …, Semenov YR et al.

J Am Acad Dermatol 2022

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors

Wongvibulsin S, Pahalyants V, …, Semenov YR et al.

Nature Medicine 2022

Germline variants associated with immune checkpoint inhibitor toxicity

Groha S, Alaiwi SA, …, Semenov YR et al.

npj Precision Oncology 2022

Prediction of early-stage melanoma recurrence using clinical and histopathologic features

Wan G, Nguyen N, Liu F, …, Semenov YR et al.